Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Evinova has partnered with QLHC to incorporate its RPM solution into the I-SPY 2.2 trial of various breast cancer treatments.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

The United States is experiencing a multi-state measles outbreak, resulting in the highest case spike since 2019.

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...